What's in Amgen's pipeline?

Amgen has 220 drugs in our index: 66 marketed, 0 filed, 66 in Phase 3, 31 in Phase 2, 57 in Phase 1.

Which companies overlap with Amgen's portfolio?

Top competitors by shared drug class: Pfizer, GlaxoSmithKline, Hoffmann-La Roche, Assistance Publique - Hôpitaux de Paris, Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/amgen.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Amgen — Portfolio Competitive Intelligence Brief

Amgen (AMGN) pipeline: 66 marketed, 0 filed, 66 Phase 3, 31 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

AMGN (NASDAQ) 66 marketed 0 filed 66 Phase 3 31 Phase 2 57 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Imdelltra (Amg757)	TARLATAMAB	marketed			Oncology	2025-01-01
Lumakras	SOTORASIB	marketed		GTPase KRas	Oncology	2021-01-01
Aimovig	ERENUMAB	marketed		Calcitonin-gene-related peptide receptor	Neuroscience	2018-01-01
Corlanor	IVABRADINE	marketed	Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker	Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1	Cardiovascular	2015-01-01
Imlygic	TALIMOGENE LAHERPAREPVEC	marketed			Oncology	2015-01-01
Blincyto	blinatumomab	marketed	Bispecific CD19-directed CD3-directed T Cell Engager	B-lymphocyte antigen CD19	Oncology	2014-01-01
Otezla	APREMILAST	marketed	Phosphodiesterase 4 Inhibitor [EPC]	PDE4	Immunology	2014-01-01
Kyprolis	carfilzomib	marketed	Proteasome Inhibitor [EPC]	Proteasome subunit beta type-5	Oncology	2012-01-01
Prolia	DENOSUMAB	marketed	RANK Ligand Inhibitor [EPC]	Tumor necrosis factor ligand superfamily member 11	Oncology	2010-01-01
Nplate	ROMIPLOSTIM	marketed	Thrombopoietin Receptor Agonist [EPC]	Thrombopoietin receptor	Cardiovascular	2008-01-01
Sensipar	CINACALCET	marketed	Calcium-sensing Receptor Agonist	Extracellular calcium-sensing receptor	Oncology	2004-01-01
Neulasta	PEGFILGRASTIM	marketed	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor	Hematology	2002-01-01

Therapeutic area mix

Oncology · 32
Immunology · 20
Other · 15
Cardiovascular · 12
Hematology · 6
Bone metabolism / Oncology · 5
Neurology · 4
Oncology, Bone Metabolism · 3
Metabolic · 3
Bone metabolism / Osteoporosis · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 10 shared drug classes
GlaxoSmithKline · 9 shared drug classes
Hoffmann-La Roche · 9 shared drug classes
Assistance Publique - Hôpitaux de Paris · 8 shared drug classes
Merck Sharp & Dohme LLC · 8 shared drug classes
Sanofi · 7 shared drug classes
Sandoz · 7 shared drug classes
AstraZeneca · 6 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Amgen:

Cite this brief

Drug Landscape (2026). Amgen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amgen. Accessed 2026-05-13.